EndocrineAug 19, 2026

Heart and kidney outcomes with combined SGLT2 inhibitor and GLP-1 receptor agonist treatment compared to each drug alone

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 20, 2026

Abstract

This exploratory network meta-analysis integrates data from randomized controlled trials to compare cardiorenal outcomes of SGLT2 inhibitors and GLP-1 receptor agonists.

SGLT2 inhibitors and GLP-1 receptor agonists each show potential for cardiorenal protection in specific populations.
The combined effect of SGLT2 inhibitors and GLP-1 receptor agonists on cardiorenal outcomes has not been previously tested in dedicated trials.
Existing data from randomized controlled trials were utilized to assess the comparative effectiveness of these medications against placebo.
Findings may help inform future research directions regarding the combined use of these therapies.

Simplified

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) each provide cardiorenal protection in trials of selected populations, but their combined effect has not been tested in dedicated head-to-head randomized trials. We performed an exploratory network meta-analysis (NMA) that integrated subgroup data from existing randomized controlled trials (RCTs) to compare SGLT2i, GLP-1RA, and concomitant SGLT2i + GLP-1RA use against placebo on cardiorenal outcomes.

Full Text

Full text is available at the source.

View Full Text ↗

Heart and kidney outcomes with combined SGLT2 inhibitor and GLP-1 receptor agonist treatment compared to each drug alone

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief